Drugs / Octanorm
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03686969 | Aug → Nov 2018 | dermatomyositis | Octapharma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03988426 | Mar 2017 → Jan 2018 | immunodeficiency disease | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT03907241 | Mar 2016 → Sep 2019 | immunodeficiency disease | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT01888484 | Mar 2014 → Jun 2020 | immunodeficiency disease | Octapharma | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-23 | Octapharma | Journal of Clinical Immunology Publishes Octapharma USA Research on cutaquig® Evaluating PI Treatment Options octapharma.com ↗ |
| 2022-01-18 | Octapharma | European authorities expand the indication for cutaquig® for patients with secondary immunodeficiencies octapharma.com ↗ |
| 2020-09-15 | Octapharma | Octapharma USA Announces Medicare Part B Approval of cutaquig® 16.5% for Adult PI Patients octapharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octanorm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03686969 ↗ |
| Known as | cutaquig | “Octanorm (cutaquig®) is a 16.5% human normal immunoglobulin solution developed by Octapharma for subcutaneous administration (SCIG).” NCT03988426 ↗1“Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG” PMID 30778345 ↗ Feb 2019 |
| Modality | Protein / enzyme biologic | “human normal immunoglobulin for subcutaneous (SC) administration” NCT01888484 ↗ |
| Route | Subcutaneous | “human normal immunoglobulin for subcutaneous (SC) administration” NCT01888484 ↗ |